Rhythm Biosciences Limited

ASX:RHY Stock Report

Market Cap: AU$32.3m

Rhythm Biosciences Valuation

Is RHY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RHY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RHY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RHY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHY?

Key metric: As RHY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RHY. This is calculated by dividing RHY's market cap by their current revenue.
What is RHY's PS Ratio?
PS Ratio20.6x
SalesAU$1.69m
Market CapAU$32.32m

Price to Sales Ratio vs Peers

How does RHY's PS Ratio compare to its peers?

The above table shows the PS ratio for RHY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.6x
IIQ INOVIQ
31.8x70.9%AU$50.7m
AHX Apiam Animal Health
0.4xn/aAU$84.0m
MAP Microba Life Sciences
5.9x38.5%AU$76.1m
FCG Freedom Care Group Holdings
0.1xn/aAU$4.0m
RHY Rhythm Biosciences
20.6xn/aAU$32.3m

Price-To-Sales vs Peers: RHY is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (9.6x).

Price to Sales Ratio vs Industry

How does RHY's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.61m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
RHY 20.6xIndustry Avg. 1.5xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RHY is expensive based on its Price-To-Sales Ratio (20.6x) compared to the Oceanic Healthcare industry average (1.5x).

Price to Sales Ratio vs Fair Ratio

What is RHY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RHY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.03

7D

0.5%

1Y

24.1%

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

7D

0%

1Y

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

7D

-3.0%

1Y

32.7%